Loading...
Loading...
XLO| Name | Value |
|---|---|
| Revenues | 2.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 2.9M |
| Operating Expense | 16.8M |
| Operating I/L | -13.9M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.0M |
| Pretax | -13.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -13.3M |
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing immunotherapies to enhance the immune system of cancer patients. Their checkpoint inhibitor program features XTX101, a tumor-selective anti-CTLA-4 mAb currently in Phase 1/2 clinical trials for solid tumors. Additionally, the company is advancing cytokine programs, including XTX202, XTX301, and XTX401, which are modified forms of IL-2, IL-12, and IL-15 respectively, designed to be activated by tumor microenvironment-associated proteases. These innovative therapies aim to generate revenue by addressing unmet medical needs in cancer treatment and potentially securing partnerships with pharmaceutical companies.
